Greater Cannabis Company (GCAN) Non Operating Income (2018 - 2025)
Greater Cannabis Company's (GCAN) quarterly Non Operating Income came in at $1313.0 in Q3 2025, up 122.95% year-on-year from $588.93 in Q3 2024, and up 100.38% quarter-over-quarter from -$342602.0 in Q2 2025.
Greater Cannabis Company (GCAN) Non Operating Income (2018 - 2025) Analysis & Trends
Greater Cannabis Company's Non Operating Income history runs 8 years deep, the most recent figure standing at $1313.0 for Q3 2025.
- On a quarterly basis, Non Operating Income rose 122.95% year-over-year to $1313.0 in Q3 2025; TTM through Dec 2025 was -$401264.0, a 1662.64% decrease from a year earlier, with the FY2025 full-year figure at -$1627.0, up 92.85% from the prior year.
- Non Operating Income climbed to $1313.0 in Q3 2025 per GCAN's latest filing, from -$342602.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $23510.0 in Q2 2021 and bottomed at -$342602.0 in Q2 2025.
- The 5-year median for Non Operating Income is -$5722.0 (2024), against an average of -$46283.2.
- Biggest YoY gain for Non Operating Income was 122.95% in 2025; the steepest drop was 5953.04% in 2025.
- Year by year, Non Operating Income stood at -$76229.0 in 2021, then jumped by 93.27% to -$5134.0 in 2022, then surged by 44.8% to -$2834.0 in 2023, then slumped by 101.94% to -$5723.0 in 2024, then surged by 122.94% to $1313.0 in 2025.
- Per Business Quant, the three latest GCAN Non Operating Income figures stand at $1313.0 (Q3 2025), -$342602.0 (Q2 2025), and -$59975.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -7.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Greater Cannabis Company | 255,226.94 | 255,226.94 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,313.00 |
| Jun 30, 2025 | -342,602.00 |
| Mar 31, 2025 | -59,975.00 |
| Dec 31, 2024 | -5,723.00 |
| Sep 30, 2024 | -5,722.00 |
| Jun 30, 2024 | -5,660.00 |
| Mar 31, 2024 | -5,660.00 |
| Dec 31, 2023 | -2,834.00 |
| Sep 30, 2023 | -2,965.00 |
| Jun 30, 2023 | -3,639.00 |
| Mar 31, 2023 | -3,600.00 |
| Dec 31, 2022 | -5,134.00 |
| Sep 30, 2022 | -53,472.00 |
| Jun 30, 2022 | -19,371.00 |
| Mar 31, 2022 | -105,256.00 |
| Dec 31, 2021 | -76,229.00 |
| Sep 30, 2021 | -177,940.00 |
| Jun 30, 2021 | 23,510.00 |
| Mar 31, 2021 | -28,421.00 |
| Dec 31, 2020 | -329,258.00 |